Konstantin Adamsky
Director/Board Member at FILAMENT HEALTH CORP.
Konstantin Adamsky active positions
Companies | Position | Start | End |
---|---|---|---|
FILAMENT HEALTH CORP. | Director/Board Member | 23/08/2022 | - |
Independent Dir/Board Member | 23/08/2022 | - |
Career history of Konstantin Adamsky
Former positions of Konstantin Adamsky
Companies | Position | Start | End |
---|---|---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Chief Executive Officer | - | 01/08/2017 |
Chief Operating Officer | 01/08/2017 | 01/10/2020 | |
Levco Pharmaceuticals Ltd. | Chief Operating Officer | - | - |
Training of Konstantin Adamsky
Weizmann Institute of Science | Doctorate Degree |
Statistics
International
Israel | 4 |
Canada | 2 |
Operational
Chief Executive Officer | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
FILAMENT HEALTH CORP. | Health Technology |
Private companies | 2 |
---|---|
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | Health Technology |
Levco Pharmaceuticals Ltd. |
- Stock Market
- Insiders
- Konstantin Adamsky
- Experience